Hiv vaccine news 2017

Here are some notable HIV vaccine news stories from 2017:

  1. HVTN 702 trial begins: In September 2017, the HIV Vaccine Trials Network (HVTN) launched the HVTN 702 trial, a large-scale clinical trial testing a new HIV vaccine in South Africa. The trial aimed to enroll 5,400 healthy adults aged 18-35 and evaluate the safety and efficacy of the vaccine.
  2. RV144 vaccine shows long-term protection: In June 2017, researchers published a study in The Lancet Infectious Diseases showing that the RV144 vaccine, developed by the US Military HIV Research Program, provided long-term protection against HIV infection. The study found that the vaccine reduced the risk of HIV infection by 31.2% over a period of 3.5 years.
  3. Imbokodo trial begins: In July 2017, the National Institute of Allergy and Infectious Diseases (NIAID) launched the Imbokodo trial, a Phase IIb clinical trial testing a new HIV vaccine in South Africa. The trial aimed to enroll 2,600 women aged 18-35 and evaluate the safety and efficacy of the vaccine.
  4. HVTN 505 trial results published: In August 2017, researchers published the results of the HVTN 505 trial, which tested a combination of two HIV vaccines in 2,500 healthy adults. The study found that the vaccine combination did not provide significant protection against HIV infection, but did show some signs of immune response.
  5. New HIV vaccine candidate shows promise: In October 2017, researchers announced the development of a new HIV vaccine candidate, called Ad26.Mos.HIV, which showed promising results in early-stage clinical trials. The vaccine used a combination of two adenovirus vectors to stimulate an immune response against HIV.
  6. HIV vaccine development receives funding boost: In November 2017, the US government announced a $100 million funding boost for HIV vaccine development, aimed at accelerating the development of new vaccines and treatments.

These are just a few of the notable HIV vaccine news stories from 2017. While progress has been made, there is still much work to be done to develop an effective HIV vaccine.